Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares RepurchasedReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Onconetix (ONCO) EBIAT (2023 - 2025)

Onconetix (ONCO) has disclosed EBIAT for 2 consecutive years, with -$29.4 million as the latest value for Q4 2024.

  • On a quarterly basis, EBIAT fell 31.71% to -$29.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$58.7 million, a 56.89% decrease, with the full-year FY2024 number at -$58.7 million, down 56.89% from a year prior.
  • EBIAT was -$29.4 million for Q4 2024 at Onconetix, down from -$3.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$2.8 million in Q1 2023 to a low of -$29.4 million in Q4 2024.